(1-(cyclohexylmethyl)piperidin-4-yl)methanol | 148703-16-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-(cyclohexylmethyl)piperidin-4-yl)methanol
• 英文别名: [1-(cyclohexylmethyl)piperidin-4-yl]methanol
• CAS: 148703-16-6
• 化学式: C₁₃H₂₅NO
• 分子量: 211.348
• InChiKey: KDSQRWFNKDSQNV-UHFFFAOYSA-N

物化性质

• 沸点：
  315.2±15.0 °C(Predicted)
• 密度：
  0.977±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氨基-5-氯-2-甲氧基苯甲酸 、 (1-(cyclohexylmethyl)piperidin-4-yl)methanol 在 N,N'-羰基二咪唑 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以31%的产率得到[1-(cyclohexylmethyl)-4-piperidyl]methyl 4-amino-5-chloro-2-methoxybenzoate
  参考文献：
  名称：

  乙酰胆碱酯酶抑制剂和5-羟色胺受体4激动剂 的化合物，其制备方法及其药物组合物

  摘要：

  本发明涉及式(Ⅰ)化合物：以及其神经性对映异构体、其酸盐、其水合物或其溶剂化物。在众多可能的含义中，X表示卤素，Y表示氧原子；所有的系数m、n、r和s的值为1，R表示甲基，R'表示环烷基。本发明还包括制备上述化合物的方法和包含所述化合物的药物组合物。

  公开号：

  CN105705488B

文献信息

• Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
  申请人：Tuerdi Huji

  公开号：US20050261244A1

  公开（公告）日：2005-11-24

  The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了含有N-芳基或N-杂环芳基取代的杂环化合物及其类似物的新型脲类化合物，这些化合物是人类P2Y1受体的选择性抑制剂。该发明还提供了相应的各种药物组合物以及调节P2Y1受体活性治疗对其敏感的疾病的方法。
• UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
  申请人：Chao Hannguang J.

  公开号：US20080280905A1

  公开（公告）日：2008-11-13

  The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型吡啶基或苯基脲及其类似物，它们是选择性的人类P2Y1受体抑制剂。本发明还提供了各种该类药物组成物和调节P2Y1受体活性以治疗对其反应的疾病的方法。
• ACETYLCHOLINESTERASE INHIBITOR COMPOUNDS AND 5HT4 SEROTONERGIC RECEPTOR AGONISTS, WITH PROMNSIA EFFECT, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：UNIVERSITE DE CAEN

  公开号：US20160122300A1

  公开（公告）日：2016-05-05

  Compounds are provided according to Formula (I) as well as their enantiomers and their racemics, their acid salts, their hydrates or their solvation products. Among a large number of possible meanings, X represents a halogen, Y an oxygen atom; all of the coefficients m, n, r and s have the value 1, R represents an ethyl and R′ a cycloalkyl. The invention also includes Methods of preparing the above compounds and the pharmaceutical compositions containing them also are provided.

  化合物根据公式（I）提供，以及它们的对映体和它们的混合物，它们的酸盐，它们的水合物或它们的溶剂化物。在许多可能的含义中，X代表卤素，Y代表氧原子；所有系数m，n，r和s的值均为1，R代表乙基，R′代表环烷基。该发明还包括制备上述化合物的方法以及含有它们的制药组合物。
• Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT₄R) Agonist Activities As Potential Agents against Alzheimer’s Disease: The Design of Donecopride
  作者：Christophe Rochais、Cédric Lecoutey、Florence Gaven、Patrizia Giannoni、Katia Hamidouche、Damien Hedou、Emmanuelle Dubost、David Genest、Samir Yahiaoui、Thomas Freret、Valentine Bouet、François Dauphin、Jana Sopkova de Oliveira Santos、Céline Ballandonne、Sophie Corvaisier、Aurélie Malzert-Fréon、Remi Legay、Michel Boulouard、Sylvie Claeysen、Patrick Dallemagne

  DOI：10.1021/acs.jmedchem.5b00115

  日期：2015.4.9

  In this work, we describe the synthesis and in vitro evaluation of a novel series of multitarget-directed ligands (MTDL) displaying both nanomolar dual-binding site (DBS) acetylcholinesterase inhibitory effects and partial 5-HT4R agonist activity, among which donecopride was selected for further in vivo evaluations in mice. The latter displayed procognitive and antiamnesic effects and enhanced sAPPa release, accounting for a potential symptomatic and disease-modifying therapeutic benefit in the treatment of Alzheimers disease.
• 5-HT4 RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0604494B1

  公开（公告）日：1999-07-28